Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
Chronic pain is a serious medical condition. We constructed a novel genetically-engineered Herpes Simplex virus-1 (HSV-1) for treatment of chronic pain. The new virus, T3-X, expresses the morphine-like molecule even at latency. We tested the efficacy of T3-X in a mouse model of chronic neuropathic pain. Gene transfer and expression by HSV-1 may be suitable for developing treatments for chronic pain.
|